source
- Scaling CAR-T: The hidden challenge of thousands of patient-specific manufacturing runsLegend Biotech and Johnson & Johnson’s Carvykti therapy illustrates the personal connection patients have with CAR-T, but also its unique operating model where each commercial dose is linked to an…
- Ultragenyx to consider major cost cuts after Angelman drug fails trialUltragenyx announced that its experimental therapy GTX-102 (apazunersen) for Angelman syndrome failed to meet primary and secondary endpoints in a Phase 3 study. The company said there were no dif…